Is Europe falling behind?

When it comes to regulating and producing medicalized cannabis products, different countries have a variety of approaches. The American field of medicalized cannabis has followed a very different path to Europe. 

In today’s episode, we speak with Stephen Murphy, co-founder and CEO of Prohibition Partners, a cannabis-focused business intelligence and consultancy company. Prohibition Partners LIVE, its flagship conference, will be taking place later this month.

In our conversation, we discuss the ways that Europe and North America differ when it comes to cannabis and what we can learn from those differences. 

In Europe, Murphy explains, cannabis products are held to the same standards of accountability and repeatability as other pharmaceuticals. While these high standards are certainly good practice, it doesn’t adequately consider that cannabis is a plant, which means it does not have the same stability as chemical compounds.

We discuss the lack of access this results in for patients, the differences between hemp and cannabis with higher levels of THC, and the tremendous proven environmental benefits of growing cannabis and producing hemp that could play a big role in the fight against global warming, which Stephen is eager to discuss in the upcoming Prohibition Partners LIVE conference.

Executive producer, Michael Schaeffer Omer-Man. The Cannabis Enigma podcast is a co-production of The Cannigma and Americans for Safe Access. Music by Desca.